A recent preclinical study demonstrated equivalent efficacy of [67Cu]Cu‐DOTA-EB-TATE and [177Lu]Lu‐DOTA-EB‐TATE against gene-modified BON1-SSTR2+ tumor xenografts in mice 50. The gene discussed is SSTR2; the disease is neoplasm.